EGLN3

Across TCGA pan-cancer cohorts, EGLN3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of EGLN3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where EGLN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EGLN3 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where EGLN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EGLN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+4.508	<.001	12	view →
LUAD	Male	III,IV	+2.439	<.001	9	view →
LUSC	Female	All	+3.071	<.001	8	view →
HNSC	Female	All	+1.765	<.001	8	view →
KICH	All	All	−1.262	<.001	8	view →
LIHC	All	II,III,IV	+0.929	<.001	8	view →
UCEC	All	II,III,IV	+2.192	<.001	6	view →
KIRP	Male	II,III,IV	+1.330	.002	6	view →
BRCA	All	II,III,IV	+1.294	<.001	6	view →
COAD	Female	All	−1.245	<.001	6	view →
CHOL	All	All	+2.554	<.001	4	view →
THCA	All	II,III,IV	+0.609	.021	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

EGLN3–KIRC

Open the KIRC breakdown →